New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:22 EDTSTJSt. Jude Medical warning letter not clearing event, says Citigroup
Citigroup believes the next FDA action regarding St. Jude Medical's Sylmar is likely to be a threat of injunction that normally leads to a consent decree. Further, Citi believes the FDA will ultimately have to make a determination on the safety of Durata, with the firm still believing a recall is likely. Citi says the FDA's Sylmar Warning Letter is not a clearing event, but the next step in a process that looks ominous for St. Jude. The firm keeps a Sell rating on the stock with a $32 price target.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
08:00 EDTSTJSt. Jude Medical price target lowered to $47 from $51 at Canaccord
Subscribe for More Information
April 16, 2014
15:39 EDTSTJBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
10:00 EDTSTJSt. Jude Medical falls 4.3%
Subscribe for More Information
08:33 EDTSTJSt. Jude Medical sees total Q2 CRM sales $705M-$735M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical sees FY14 consolidated adjusted EPS $3.95-$4.00
Subscribe for More Information
07:33 EDTSTJSt. Jude Medical sees Q2 consolidated adjusted EPS 99c-$1.01, consensus $1.00
Sees Q2 revenue $1.38B-$1.46B, consensus $1.44B.
07:31 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 96c, consensus 95c
Subscribe for More Information
April 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
09:23 EDTSTJBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use